Option Care Health (OPCH) shares came into focus after the company reported fourth quarter and full year 2025 results, combining higher sales with margin pressure from biosimilar adoption, reaffirmed guidance and a larger share repurchase program.

At a share price of US$32.46, Option Care Health has seen pressure recently, with a 7 day share price return of a 10.06% decline and a 1 month share price return of a 4.53% decline. This is in contrast to the 90 day share price return of 5.84% and the 5 year total shareholder return of 74.33%, which indicate a longer term uptrend that recent earnings news and the expanded buyback appear to have interrupted rather than reversed.

If earnings volatility and reimbursement headlines have you reassessing healthcare exposure, it could be a good moment to look at our screener of 28 healthcare AI stocks as potential next ideas.

With revenue and earnings guidance roughly aligned with expectations and a larger buyback now in place, the key question for you is whether Option Care Health at US$32.46 still leaves a margin of safety or if the market is already pricing in future growth.

Most Popular Narrative: 18.5% Undervalued

Option Care Health’s most followed narrative pegs fair value at $39.82, which sits well above the current $32.46 share price and frames today’s debate.

Investments in technology (AI, analytics, digital infrastructure) and clinical resource efficiency projects are supporting increased operating leverage and process automation, which is improving net margins and cash flow generation.

Want to see what happens when rising margins, steady revenue gains, and a richer earnings multiple all pull in the same direction? The narrative sets out a tight group of assumptions around growth, profitability, and valuation that underpin that $39.82 figure.

Result: Fair Value of $39.82 (UNDERVALUED)

However, you still have to weigh risks like reimbursement pressure from payers and shifting therapy mix, which could squeeze margins and test that 18.5% undervalued narrative.

Another View: What The P/E Is Saying

That 18.5% undervalued narrative sits awkwardly next to the current P/E of 24.5x, which is higher than the US Healthcare industry at 23.7x, but lower than the 63.7x peer average and close to a 25.3x fair ratio. Is this a modest cushion or a thin one?

Next Steps

If this mix of optimism and concern feels familiar, use it as a prompt to move quickly. Test the numbers yourself and see how they stack up against 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

Before you move on, give yourself options. A few minutes with the right screeners can surface opportunities you might otherwise miss entirely.

• Target potential value by scanning companies that our tools flag as 49 high quality undervalued stocks based on fundamentals and current pricing.
• Prioritize staying power by checking out a solid balance sheet and fundamentals stocks screener (41 results) that can help you focus on financially resilient names.
• Spot lesser known opportunities by running through a screener containing 24 high quality undiscovered gems that highlight quality businesses flying under most radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.